Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03341052 · ClinicalTrials.gov registry record · NA

Characterization of Bile Acid Pathway in Obesity

A NA study of Obesity, sponsored by Mayo Clinic.

Completed
Registry status
NA
Development phase
16
Enrollment target
1
Study location

NCT03341052: Completed NA study of Obesity, sponsored by Mayo Clinic.

NCT03341052 is a NA study of Obesity that has completed, run by Mayo Clinic. The registered enrollment target is 16 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03341052, a NA study of Obesity, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
NA
Development phase
16 participants
Enrollment target
1
Study location

Study Summary

It is unknown whether the bile acid pathway is altered in obesity. This study is designed to compare obesity and health to determine if the bile acid pathway differs depending on health state.

Primary Outcome

Change in 48h-fecal bile acid excretion (μmol/L) between baseline and high fat diet

Conditions Studied

Interventions

  • OTHER Normal Diet
  • OTHER High Fat Diet
  • OTHER Low Fat Diet

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2017-11-14
Est. Completion 2021-10-09
Phase NA
Mayo Clinic

2,844 total trials

What the finished NCT03341052 record still lists

NCT03341052 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 3 interventions - of which Normal Diet is the first listed.

NCT03341052 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT03341052 about?

NCT03341052 is a clinical study titled "Characterization of Bile Acid Pathway in Obesity". It is unknown whether the bile acid pathway is altered in obesity. This study is designed to compare obesity and health to determine if the bile acid pathway differs depending on health state.

What is the current status of trial NCT03341052?

This trial is currently completed. It is a NA study. The enrollment target is 16 participants. The study started on 2017-11-14. Estimated completion is 2021-10-09.

What conditions does trial NCT03341052 study?

This clinical trial studies the following conditions: Obesity.

What interventions are being tested in trial NCT03341052?

The interventions under investigation include: Normal Diet (OTHER), High Fat Diet (OTHER), Low Fat Diet (OTHER).

Who is sponsoring clinical trial NCT03341052?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03341052 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03341052's enrollment target sits among peer trials

16 993rd of 1053 higher than 56 of 1,053 other Obesity trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02422641 · 16 participants · Phase 2

    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

  • NCT02851758 · 16 participants · NA

    Transplantation of Autologously Derived Mitochondria Following Ischemia

  • NCT03291028 · 16 participants

    Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

  • NCT03425526 · 16 participants · Phase 1

    Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03341052, the US trial registry maintained by the National Library of Medicine. NCT03341052 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.